Cohort profile: The Singapore Breast Cancer Cohort (SGBCC), a multi-center breast cancer cohort for evaluation of phenotypic risk factors and genetic markers.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
11
2020
accepted:
30
03
2021
entrez:
26
4
2021
pubmed:
27
4
2021
medline:
13
10
2021
Statut:
epublish
Résumé
This article aims to provide a detailed description of the Singapore Breast Cancer Cohort (SGBCC), an ongoing multi-ethnic cohort established with the overarching goal to identify genetic markers for breast cancer risk, prognosis and treatment response, as well as to understand the ethnic differences in disease risk and outcome in an Asian setting. The cohort comprises of breast cancer patients aged 21 years and above from six public hospitals which diagnose and treat nearly 76% breast cancer cases in Singapore. Self-reported data on sociodemographic and lifestyle, reproductive risk factors, medical history and family history of breast or ovarian cancer is collected using a structured questionnaire. Clinical data on tumour characteristics, and treatment modalities are obtained through medical record. Bio-specimens (blood or saliva) is collected at recruitment. Follow-up on survival information is done through routine linkage with the Registry of Births and Deaths. As of 31 December 2016, 7,768 subjects have been recruited to the study with 76% subjects contributed bio-specimens. The SGBCC provides a valuable platform which offers a unique, large and rich resource for new research ideas on breast cancer related phenotypic risk factors and genetic markers.
Identifiants
pubmed: 33901219
doi: 10.1371/journal.pone.0250102
pii: PONE-D-20-34111
pmc: PMC8075208
doi:
Substances chimiques
Genetic Markers
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0250102Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nat Commun. 2020 Jul 31;11(1):3833
pubmed: 32737321
Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):126-135
pubmed: 27697780
Int J Cancer. 2005 Jan 10;113(2):302-6
pubmed: 15386413
Pharmacogenomics. 2015;16(10):1161-78
pubmed: 25978008
N Engl J Med. 2021 Feb 4;384(5):428-439
pubmed: 33471991
Int J Epidemiol. 2018 Jun 1;47(3):699-699j
pubmed: 29452397
J Vis Exp. 2010 Nov 22;(45):
pubmed: 21189466
Br J Cancer. 2014 Jan 7;110(1):224-9
pubmed: 24169349
PLoS One. 2012;7(2):e30995
pubmed: 22363531
BMC Cancer. 2006 Nov 02;6:261
pubmed: 17078893
BMC Genomics. 2017 Jan 5;18(1):26
pubmed: 28056765
Nat Genet. 2014 Aug;46(8):886-90
pubmed: 25038754
Br J Cancer. 1996 Mar;73(5):680-6
pubmed: 8605107
Eur J Cancer. 2013 Feb;49(3):703-9
pubmed: 23040889
Am J Hum Genet. 2019 Jan 3;104(1):21-34
pubmed: 30554720
Singapore Med J. 2012 Jan;53(1):3-9; quiz 10
pubmed: 22252175
Int J Epidemiol. 2017 Dec 1;46(6):1740-1741g
pubmed: 28180256
Nature. 2017 Nov 2;551(7678):92-94
pubmed: 29059683
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Hum Mol Genet. 2013 Jun 15;22(12):2539-50
pubmed: 23535825
J Med Screen. 2015 Dec;22(4):194-200
pubmed: 26081449
J Natl Cancer Inst. 2015 Apr 13;107(7):
pubmed: 25868578
Br J Cancer. 2009 Jun 2;100(11):1806-11
pubmed: 19401693